Related Experiment Videos

High-dose chemotherapy of breast cancer: current status and developmental strategies

J Crown¹, G Raptis, N Hamilton

¹St Vincent's Hospital, Department of Medical Oncology, Elm Park, Dublin, Ireland.

European Journal of Cancer (Oxford, England : 1990)

|January 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Parallel EEG-fNIRS assessments of covert cognition in behaviorally non-responsive ICU patients: A multi-task feasibility study in a case of acute motor sensory axonal neuropathy.

Journal of neurology·2025

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

See all related articles